The trial compared the combo against the investigator's choice of tyrosine kinase inhibitor monotherapy - either lenvatinib ...

Sorafenib is an oral multikinase inhibitor that inhibits tumor growth and proliferation by interfering with several receptor tyrosine kinases involved in the pathogenesis and perpetuation of ...

The U.S. Food and Drug Administration has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for ...

Purpose: The role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma (mRCC) is reviewed. Conclusion: The tyrosine kinase inhibitors sorafenib and sunitinib offer ...

Approval of Opdivo plus Yervoy combination was based on results from the Phase III CheckMate-9DW trial, which demonstrated ...

The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination with Yervoy ® (ipilimumab) for the first-line treatment of adult patients with unresectable or metastatic ...

The combination therapy can be used as first-line treatment for unresectable or metastatic forms of the cancer.

Findings from the CheckMate 9DW trial support the FDA approval of nivolumab and ipilimumab in unresectable hepatocellular ...

At 3 years, Opdivo plus Yervoy led to an overall survival rate of 38% in patients with unresectable or metastatic hepatocellular carcinoma, compared to 24% with lenvatinib or sorafenib monotherapy.